OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
January 29, 2025
Host Chris Miglino interviews CEO Jason Matuszewski. He talks about their product, the way that it’s produced, recovered, proccessed, and the way that it supports bodies to recover from wounds.
January 29, 2025
January 14, 2025
July 16, 2024
July 9, 2024